RAPT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 108174 min ago

@ $24.99

Išleistas: 13 vas. 2024 @ 22:43

Grąža: -67.59%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 0.73 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	294 633
Vidutinė apimtis	1.35M
Rinkos kapitalizacija	281.86M
EPS	$0 ( 2024-03-12 )
Kita pelno data	( $-0.780 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.66
ATR14	$0.0110 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Robbins Wendye	Buy	6 925	Stock Option (right to buy)
2024-03-28	Gray Mary Ann	Buy	8 574	Stock Option (right to buy)
2024-03-28	Rieflin William Jl	Buy	11 871	Stock Option (right to buy)
2024-01-31	Ho William	Buy	75 000	Employee Stock Option (right to buy)
2024-01-31	Young Rodney Kb	Buy	90 000	Employee Stock Option (right to buy)

INSIDER POWER
94.05
Last 100 transactions
Buy: 3 742 359 \| Sell: 63 895

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: -0.76 (moderate negative)

Signal:(31.973) Neutral

Rapt Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RDUS	0.903
ICON	0.901
ATCX	0.9
SYKE	0.898
PAE	0.889
BRACU	0.886
RCON	0.884
CLBT	0.884
ABNB	0.878
DKNG	0.876

10 Labiausiai neigiamai susiję koreliacijos
VIEW	-0.886
SBBP	-0.863
TUEM	-0.855
LGHL	-0.855
ARDS	-0.848
LCAP	-0.844
RPTX	-0.839
AHPI	-0.839
MTEX	-0.838
NAKD	-0.838

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Rapt Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.58
( weak negative )

-0.62
( weak negative )

0.00
( neutral )

-0.52
( weak negative )

0.00
( neutral )

0.25
( neutral )

Rapt Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2023
Pajamos:	$0
Bruto pelnas:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2022
Pajamos:	$1.53M
Bruto pelnas:	$-1.28M (-83.82 %)
EPS:	$-2.52

FY	2021
Pajamos:	$3.81M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.53

Financial Reports:

No articles found.

Rapt Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.